Histological Assessments for Anabolic Effects in Teriparatide/abaloparatide Administered Rodent Models

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2024 Dec 4

PMID 39630261

Authors

Tomoka Hasegawa

Tomomaya Yamamoto

Mai Haraguchi-Kitakamae

Hiromi Hongo

Yan Shi

Jiaxin Cui

Xuanyu Liu

Qi Yao

Miki Abe

Haruhi Maruoka

Ayako Yokoyama

Tamaki Sekiguchi

Akito Makino

Norio Amizuka

Affiliations

Soon will be listed here.

Abstract

Parathyroid hormone (PTH) is thought to induce remodeling-based bone formation by promoting osteoclastic activity, a process known as cellular coupling. Our research has shown that the frequency of PTH administration affects trabecular number and thickness. High-frequency PTH administration induced remodeling-based bone formation, while less frequent administration induced both remodeling-based and modeling-based bone formation. Additionally, we found that specific bone sites influence whether remodeling-based or modeling-based bone formation is more likely to occur. Additionally, while PTH significantly increases trabecular bone, it also causes cortical porosis. Our research on the femoral diaphysis showed that PTH administration resulted in the invasion of blood vessels and osteoclasts into the cortical bone. Abaloparatide acts similarly to teriparatide through the parathyroid hormone receptor type 1 (PTH1R) but may have a wider anabolic window due to its lesser impact on bone resorption. Our mouse studies with abaloparatide showed similar results to those seen in human patients, with increased preosteoblastic cell populations and wider anabolic windows when compared with teriparatide. Abaloparatide-induced bone formation cannot be explained solely by remodeling-based bone formation, indicating the need for further research into modeling-based bone formation.

References

Yamamoto T, Hasegawa T, Fraitas P, Hongo H, Zhao S, Yamamoto T . Histochemical characteristics on minimodeling-based bone formation induced by anabolic drugs for osteoporotic treatment. Biomed Res. 2021; 42(5):161-171. DOI: 10.2220/biomedres.42.161. View

Jee W, Tian X, Setterberg R . Cancellous bone minimodeling-based formation: a Frost, Takahashi legacy. J Musculoskelet Neuronal Interact. 2007; 7(3):232-9. View

Yamamoto T, Hasegawa T, Sasaki M, Hongo H, Tsuboi K, Shimizu T . Frequency of Teriparatide Administration Affects the Histological Pattern of Bone Formation in Young Adult Male Mice. Endocrinology. 2016; 157(7):2604-20. DOI: 10.1210/en.2015-2028. View

Hasegawa T, Yamamoto T, Sakai S, Miyamoto Y, Hongo H, Qiu Z . Histological Effects of the Combined Administration of Eldecalcitol and a Parathyroid Hormone in the Metaphyseal Trabeculae of Ovariectomized Rats. J Histochem Cytochem. 2018; 67(3):169-184. PMC: 6393841. DOI: 10.1369/0022155418806865. View

Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Diez-Perez A . The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18(1):9-17. DOI: 10.1359/jbmr.2003.18.1.9. View

Schweser K, Crist B . Osteoporosis: a discussion on the past 5 years. Curr Rev Musculoskelet Med. 2017; 10(2):265-274. PMC: 5435641. DOI: 10.1007/s12178-017-9410-y. View

Freitas P, Li M, Ninomiya T, Nakamura M, Ubaidus S, Oda K . Intermittent PTH administration stimulates pre-osteoblastic proliferation without leading to enhanced bone formation in osteoclast-less c-fos(-/-) mice. J Bone Miner Res. 2009; 24(9):1586-97. DOI: 10.1359/jbmr.090413. View

Dhillon R, Xie C, Tyler W, Calvi L, Awad H, Zuscik M . PTH-enhanced structural allograft healing is associated with decreased angiopoietin-2-mediated arteriogenesis, mast cell accumulation, and fibrosis. J Bone Miner Res. 2012; 28(3):586-97. PMC: 3540116. DOI: 10.1002/jbmr.1765. View

Jiang X, Xu C, Shi H, Cheng Q . PTH1-34 improves bone healing by promoting angiogenesis and facilitating MSCs migration and differentiation in a stabilized fracture mouse model. PLoS One. 2019; 14(12):e0226163. PMC: 6903750. DOI: 10.1371/journal.pone.0226163. View

10.

Zhao S, Hasegawa T, Hongo H, Yamamoto T, Abe M, Yoshida T . Intermittent PTH Administration Increases Bone-Specific Blood Vessels and Surrounding Stromal Cells in Murine Long Bones. Calcif Tissue Int. 2020; 108(3):391-406. DOI: 10.1007/s00223-020-00776-2. View

11.

Lotinun S, Evans G, Bronk J, Bolander M, Wronski T, Ritman E . Continuous parathyroid hormone induces cortical porosity in the rat: effects on bone turnover and mechanical properties. J Bone Miner Res. 2004; 19(7):1165-71. DOI: 10.1359/JBMR.040404. View

12.

Leder B, ODea L, Zanchetta J, Kumar P, Banks K, McKay K . Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2014; 100(2):697-706. DOI: 10.1210/jc.2014-3718. View

13.

Miller P, Hattersley G, Riis B, Williams G, Lau E, Russo L . Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016; 316(7):722-33. DOI: 10.1001/jama.2016.11136. View

14.

Hattersley G, Dean T, Corbin B, Bahar H, Gardella T . Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology. 2015; 157(1):141-9. PMC: 4701881. DOI: 10.1210/en.2015-1726. View

15.

Varela A, Chouinard L, Lesage E, Guldberg R, Smith S, Kostenuik P . One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats. Bone. 2016; 95:143-150. DOI: 10.1016/j.bone.2016.11.027. View

16.

Varela A, Chouinard L, Lesage E, Smith S, Hattersley G . One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption. J Bone Miner Res. 2016; 32(1):24-33. DOI: 10.1002/jbmr.3003. View

17.

Doyle N, Varela A, Haile S, Guldberg R, Kostenuik P, Ominsky M . Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int. 2017; 29(3):685-697. PMC: 5834552. DOI: 10.1007/s00198-017-4323-6. View

18.

Chandler H, Lanske B, Varela A, Guillot M, Boyer M, Brown J . Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone. 2018; 120:148-155. DOI: 10.1016/j.bone.2018.10.012. View

19.

Makino A, Hasegawa T, Takagi H, Takahashi Y, Hase N, Amizuka N . Frequent administration of abaloparatide shows greater gains in bone anabolic window and bone mineral density in mice: A comparison with teriparatide. Bone. 2020; 142:115651. DOI: 10.1016/j.bone.2020.115651. View

20.

Lindsay R, Nieves J, Formica C, HENNEMAN E, Woelfert L, Shen V . Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997; 350(9077):550-5. DOI: 10.1016/S0140-6736(97)02342-8. View